A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

ClinicalTrials.gov ID: NCT05692180

Public ClinicalTrials.gov record NCT05692180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

Study identification

NCT ID: NCT05692180
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Asthma

Interventions

Benralizumab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 6 Years to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 4, 2023
Primary completion: May 4, 2030
Completion: May 15, 2032
Last update posted: May 5, 2026

2023 – 2032

United States locations

U.S. sites: 28
U.S. states: 19
U.S. cities: 27

Facility	City	State	ZIP	Site status
Research Site	Mobile	Alabama	36608	Withdrawn
Research Site	Montgomery	Alabama	36106	Withdrawn
Research Site	Tucson	Arizona	85724	Recruiting
Research Site	Little Rock	Arkansas	72202	Withdrawn
Research Site	Madera	California	93636	Withdrawn
Research Site	Torrance	California	90505	Recruiting
Research Site	Washington D.C.	District of Columbia	20010	Recruiting
Research Site	Miami	Florida	33144	Recruiting
Research Site	Miami	Florida	33184	Recruiting
Research Site	Ocala	Florida	34471	Completed
Research Site	Owensboro	Kentucky	42301	Recruiting
Research Site	Lafayette	Louisiana	70508	Recruiting
Research Site	New Orleans	Louisiana	70112	Withdrawn
Research Site	Glenn Dale	Maryland	20769	Recruiting
Research Site	Boston	Massachusetts	02114	Not yet recruiting
Research Site	Ridgeland	Mississippi	39157	Withdrawn
Research Site	Kansas City	Missouri	64108	Completed
Research Site	Lincoln	Nebraska	68510	Withdrawn
Research Site	Brick	New Jersey	08724	Withdrawn
Research Site	Northfield	New Jersey	08225	Recruiting
Research Site	The Bronx	New York	10459	Recruiting
Research Site	Cincinnati	Ohio	45229	Recruiting
Research Site	Cleveland	Ohio	44106	Recruiting
Research Site	Charleston	South Carolina	29425	Completed
Research Site	Dallas	Texas	75235	Withdrawn
Research Site	San Antonio	Texas	78229	Recruiting
Research Site	Tyler	Texas	75708	Recruiting
Research Site	Morgantown	West Virginia	26506	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05692180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05692180 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →